NCT05514990 2025-11-14
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
University of Southern California
Phase 1/2 Active not recruiting
Clinical Trials
7 trialsNCT03605719 2023-10-06
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
Emory University
Phase 1 Completed
NCT02514382 2023-08-14
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Southern California
Phase 1 Completed
NCT02444546 2023-04-24
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Mayo Clinic
Phase 1 Completed
NCT03723915 2022-10-05
Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer
Northwestern University
Phase 2 Terminated
NCT03015922 2020-01-22
MUKeleven
University of Leeds
Phase 1 Unknown
NCT03282188 2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2 Withdrawn